Last updated on: 15/10/2020
Name of organisation
1) Department/Research groupUniversity of Southern Denmark Pharmacoepi center
2) Organisation/affiliationUniversity of Southern Denmark
Short Name in the inventoryUniversity of Southern Denmark Pharmacoepi center
Administrative Contact
Title Professor
Last name Hallas
First name Jesper
Address line 1JB Winsløwsvej 19,2
Address line 2
Address line 3
CityOdense C
PostcodeDK-5000
CountryDenmark
Phone number (incl. country code)45-65503010
Alternative phone number45-60191182
Fax number (incl. country code)45-65916089
Scientific Contact
Title Professor
Last name Hallas
First name Jesper
Address line 1JB Winsløwsvej 19,2
Address line 2
Address line 3
CityOdense C
PostcodeDK-5000
CountryDenmark
Phone number (incl. country code)45-65503010
Alternative phone number45-60191182
Fax number (incl. country code)45-65916089
2. Description
The University of Southern Denmark Pharmcoepi Center is a pharmacoepidemiological research group embedded within the department of clinical pharmacology and pharmacy at the University of Southern Denmark.
The group consists of app 18 persons, including senior epidemiologists, data managers, administrators and PhD students. Its research is focussed on applied, classical pharmacoepidemiology within a wide range of diseases and on method development within fields such as drug utilization research, self-controlled designs and screening of big data for unknown associations.
The group has access to a wide range of nation-wide Danish data sources, including but not limited to the National Prescription Register, the National Patient Register and the Cancer Register. The scientific output is in the order of 70 peer-reviewed papers per year.
3. Category
University based
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Congenital Malformations
Disorders of the central nervous system
Gastrointestinal tract
Infectious diseases
Malignant disease
Musculoskeletal and joint diseases
Osteoporosis
Respiratory diseases
General practice
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Interventional Clinical Trial
Meta-Analysis
Self-controlled designs
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Between 1500 and 14999
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
No
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
Danish Statistical Institute150
OPED10
11. Registries established by centre
Drug RegistryOPED
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
EuroDURG
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
15. Interest in contract research only if free to publish results
No
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Hansen MR, Hróbjartsson A, Pottegård A, Damkier P, Larsen KS, Madsen KG,
dePont Christensen R, Kristensen MEL, Christensen PM, Hallas J. Postponement of
Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical
Trials. J Gen Intern Med. 2019 May 9. doi: 10.1007/s11606-019-05024-4. [Epub
ahead of print] PubMed PMID: 31073857.
Rasmussen ER, Pottegård A, Bygum A, von Buchwald C, Homøe P, Hallas J.
Angiotensin II receptor blockers are safe in patients with prior angioedema
related to angiotensin-converting enzyme inhibitors - a nationwide registry-based
cohort study. J Intern Med. 2019 May;285(5):553-561. doi: 10.1111/joim.12867.
Epub 2019 Jan 8. PubMed PMID: 30618189.
Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS,
Buck TC, Pottegård A, Hansen MR, Hallas J. Effect of an In-Hospital Multifaceted
Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized
Clinical Trial. JAMA Intern Med. 2018 Mar 1;178(3):375-382. doi:
10.1001/jamainternmed.2017.8274. PubMed PMID: 29379953; PubMed Central PMCID:
PMC5885912.
Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A.
Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide
case-control study from Denmark. J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9.
doi: 10.1016/j.jaad.2017.11.042. Epub 2017 Dec 4. PubMed PMID: 29217346.
Gaist D, García Rodríguez LA, Hellfritzsch M, Poulsen FR, Halle B, Hallas J,
Pottegård A. Association of Antithrombotic Drug Use With Subdural Hematoma Risk.
JAMA. 2017 Feb 28;317(8):836-846. doi: 10.1001/jama.2017.0639. PubMed PMID:
28245322.
